0001493152-21-026394.txt : 20211026 0001493152-21-026394.hdr.sgml : 20211026 20211026215355 ACCESSION NUMBER: 0001493152-21-026394 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211022 FILED AS OF DATE: 20211026 DATE AS OF CHANGE: 20211026 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Carillo Carlos N CENTRAL INDEX KEY: 0001889694 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39871 FILM NUMBER: 211350494 MAIL ADDRESS: STREET 1: 2100 E 54TH STREET NORTH CITY: SIOUX FALLS STATE: SD ZIP: 57109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001833214 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 853899721 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 W. 41ST STREET STREET 2: SUITE 202 CITY: MIAMI BEACH STATE: FL ZIP: 33140 BUSINESS PHONE: (305) 204-3338 MAIL ADDRESS: STREET 1: 300 W. 41ST STREET STREET 2: SUITE 202 CITY: MIAMI BEACH STATE: FL ZIP: 33140 FORMER COMPANY: FORMER CONFORMED NAME: Big Cypress Acquisition Corp. DATE OF NAME CHANGE: 20201120 4 1 ownership.xml X0306 4 2021-10-22 0 0001833214 SAB Biotherapeutics, Inc. SABS 0001889694 Carillo Carlos N 2100 E 54TH STREET NORTH SIOUX FALLS SD 57104 0 1 0 0 SVP Regulatory Affairs Employee Stock Option (right to buy) 1.88 2021-10-22 4 A 0 17681 A 2031-05-27 Common Stock 17681 17681 D Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer"). The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, May 24, 2021, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date. /s/ Carlos N Carillo 2021-10-26